World's first study on male pattern hair loss based on telemedical data

Research cooperation between Wellster Healthtech Group and University Medical Center Hamburg-Eppendorf

Under the title "Telemedical Care of Men with Androgenetic Alopecia Demonstrates Improved Access to Care and Patient Benefit", Spring is publishing the world's first scientific study on male pattern hair loss based on telemedical data in a research collaboration with the Medical Center Hamburg-Eppendorf. The study was published by the renowned journal “Journal of the European Academy of Dermatology and Venereology.”

Quote Johannes v. Büren

“Telemedicine platforms such as online prescription platforms represent a new type of medical care. Telemedicine has gained increasing acceptance in recent years, and its application in clinical practice is diverse. This is the world's first telemedicine study on male pattern hair loss. We believe it is important that more research be done in this area, as many tens of thousands of patients are being treated telemedically in this indication in the United States as well as in Europe.”

Structure of the study

  • Survey of 3,000 patients from the Spring database
  • Consideration of demographic factors, time windows of use and a comparison to care quality of the outpatient physician
  • Research period is March 2021 and January 2022
  • Prescribed medication was primarily the 5α-Reductase inhibitor finasteride, first line treatment for male pattern hair loss
  • Objectives of the study are to characterize patients who use telemedical services for the treatment of their male pattern hair loss and to determine the barriers to treatment that have prevented them from receiving conventional dermatological or family doctor treatment

Quote Johannes v. Büren

“This study goes well beyond the epidemiological characterization of Spring's hair loss patient cohort. Based on the scientific analysis of medical data from around 3,000 patients, it shows how online platforms can lower access barriers and thus patients can start their treatment earlier. We consider this to be particularly relevant when it comes to hair loss, since starting treatment early increases the chances of successful therapy.”

Results of the study

  • At 58 percent, the majority of participants were assigned to an early stage of hair loss (I to III from VII according to the Norton-Hamilton scale). Affected individuals thus benefit in particular from treatment that is easily accessible and started at an early stage.
  • About 65 percent of patients requested repeat prescriptions.
  • 81 percent of respondents rated the quality of medical care via MySpring as at least as good as or better than care provided in an outpatient practice.
  • Nearly all respondents (97 percent) are willing to continue telemedicine care.

Quote Johannes v. Büren

“We find it particularly interesting that patients who had already seen a doctor about their hair loss before starting their telemedicine treatment rated the quality of telemedicine care as equivalent.”

View entire study here


Interpretation of the study

The results of our study demonstrate the potentials of telemedicine to gain a substantial number of untreated patients. By reducing treatment barriers, telemedicine platforms contribute to earlier diagnosis and improved access to care, both leading to higher treatment success. This study demonstrates the patient benefit of telemedical care for men with male pattern hair loss.


Icon facebock s/wIcon Instagram s/wIcon YouTube s/w